Endothelin
- 17 September 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cellular and Molecular Life Sciences
- Vol. 68 (2), 195-203
- https://doi.org/10.1007/s00018-010-0518-0
Abstract
Endothelin-1 is the most potent vasoconstrictor agent currently identified, and it was originally isolated and characterized from the culture media of aortic endothelial cells. Two other isoforms, termed endothelin-2 and endothelin-3, were subsequently identified, along with structural homologues isolated from the venom of Actractapis engaddensis known as the sarafotoxins. In this review, we will discuss the basic science of endothelins, endothelin-converting enzymes, and endothelin receptors. Only concise background information pertinent to clinical physician is provided. Next we will describe the pathophysiological roles of endothelin-1 in pulmonary arterial hypertension, heart failure, systemic hypertension, and female malignancies, with emphasis on ovarian cancer. The potential intervention with pharmacological therapeutics will be succinctly summarized to highlight the exciting pre-clinical and clinical studies within the endothelin field. Of note is the rapid development of selective endothelin receptor antagonists, which has led to an explosion of research in the field.Keywords
This publication has 110 references indexed in Scilit:
- Estrogen Inhibits ATR Signaling to Cell Cycle Checkpoints and DNA RepairMolecular Biology of the Cell, 2009
- β-Arrestin links endothelin A receptor to β-catenin signaling to induce ovarian cancer cell invasion and metastasisProceedings of the National Academy of Sciences of the United States of America, 2009
- Isoforms of endothelin-converting enzyme-1 (ECE-1) have opposing effects on prostate cancer cell invasionBritish Journal of Cancer, 2008
- ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancerExpert Opinion on Investigational Drugs, 2008
- Endothelin inhibition delays onset of hyperglycemia and associated vascular injury in type I diabetes: Evidence for endothelin release by pancreatic islet β-cellsBiochemical and Biophysical Research Communications, 2005
- Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4)Journal of the American College of Cardiology, 2003
- RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled studyJournal of the American College of Cardiology, 2003
- Endothelins and Endothelin Receptor AntagonistsCirculation, 2000
- Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculatureEndocrinology, 1993
- Identification and characterization of endothelin converting activity in cultured bovine endothelial cellsBiochemical and Biophysical Research Communications, 1990